Alnylam makes a bull case for PhIII-ready porphyria drug, but shares sink anyway
Alnylam today offered some details on the data it has gathered from a small, early-stage study of givosiran for rare cases of porphyrias. The data provide some insights on the therapy’s positive impact in preventing fresh attacks, but the biotech’s shares $ALNY were down 3.6% in afternoon trading as analysts looked through the numbers and pondered the durability of a recent run-up in the stock price.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.